Home > Boards > Other Markets > Foreign Stock Markets > Novo Nordisk A/S (NVO)

Novo Nordisk to initiate phase 3a development of

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
TREND1 Member Profile
Member Level 
Followed By 407
Posts 54,561
Boards Moderated 38
Alias Born 12/16/01
160x600 placeholder
TREND1 Member Level  Wednesday, 08/26/15 02:14:44 PM
Re: None
Post # of 49 


Novo Nordisk to initiate phase 3a development of oral semaglutide, a once-daily oral GLP-1 analogue





Bagsværd, Denmark, 26 August 2015 - Novo Nordisk today announced the decision to initiate a phase 3a programme with oral semaglutide; a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows the encouraging results of the proof–of-concept phase 2 trial announced on 20 February 2015 and the subsequent consultations with regulatory authorities.



Novo Nordisk intends to initiate a global phase 3a programme, named PIONEER, comprising seven trials with approximately 8,000 people with type 2 diabetes. The PIONEER programme will include six safety and efficacy trials and one trial for evaluating the cardio-vascular safety of oral semaglutide. The first trial in the programme is planned for initiation in first quarter of 2016 and will investigate the efficacy and safety of once- daily oral semaglutide doses of 3 mg, 7 mg and 14 mg, compared to once-daily oral anti- diabetic sitagliptin dose of 100 mg. The remaining six trials of the PIONEER programme are all expected to be initiated during 2016.



In order to meet capacity requirements for current and future diabetes care products, including oral semaglutide, Novo Nordisk expects to invest an estimated 2 billion US dollars over the coming five years in two new production facilities; a new production facility for a range of active pharmaceutical ingredients in Clayton, North Carolina, US and a new drug-product facility in Måløv, Denmark. The final design and cost of the new production facilities will be presented for approval by the company’s board of directors in 2016.



“Delivering protein-based medicine like semaglutide in the form of a tablet and producing it on a large scale is a major challenge, and with the announcement today we have reached a significant milestone towards achieving that goal”, said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “We are excited about the opportunities oral semaglutide represents as a new oral anti-diabetic agent to further improve type 2 diabetes treatment”.










Page 2 of 2





About semaglutide

Semaglutide (NN9924) is a new glucagon-like peptide-1 (GLP-1) analogue that can help people with type 2 diabetes achieve substantial lowering of blood glucose with a low risk of hypoglycaemia. In addition, semaglutide induces weight loss by decreasing appetite and food intake. The oral formulation of semaglutide is provided in a tablet formulation with SNAC, an absorption-enhancing excipient included in the Eligen® Carrier Concept. The Eligen® technology is licenced from Emisphere Technologies, Inc.





Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,700 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube





Further information

Media:
Katrine Sperling +45 3079 6718 krsp@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com

Investors:
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com












Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888



Internet:

www.novonordisk.com

CVR no:

24 25 67 90


Company announcement No 52 / 2015








SIGNATURES





Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.



Date: August 26, 2015


NOVO NORDISK A/S



Lars Rebien Sørensen,

Chief Executive Officer







Novo Nordisk A S (NYSE:NVO)
Historical Stock Chart

1 Year : From Aug 2014 to Aug 2015
Click Here for more Novo Nordisk A S Charts.
Novo Nordisk A S (NYSE:NVO)
Intraday Stock Chart

Today : Wednesday 26 August 2015
Click Here for more Novo Nordisk A S Charts.




More NVO MessagesLatest Novo-Nordisk A/S, NVO Messages





NVO PF
TREND1 • Wed Aug 26, 2015 2:06 PM (7 minutes ago)


Inst % Owned = 7%
TREND1 • Wed Aug 26, 2015 2:05 PM (8 minutes ago)


EPS= 10.10
TREND1 • Wed Aug 26, 2015 2:04 PM (9 minutes ago)


NVO D
TREND1 • Wed Aug 26, 2015 2:03 PM (10 minutes ago)


NVO D
TREND1 • Tue Nov 4, 2014 4:33 PM


FROM DEW
TREND1 • Thu Oct 30, 2014 11:25 AM


THANKS
TREND1 • Tue Oct 28, 2014 1:36 PM


Yes—see #msg-107612584.
DewDiligence • Tue Oct 28, 2014 1:02 PM


Was NOV drop due to reaction of SNY
TREND1 • Tue Oct 28, 2014 12:01 PM


NVO D
TREND1 • Sat Oct 25, 2014 3:04 PM

Bookmark With :
Facebook MySpace Twitter Digg Del.icio.us StumbleUpon Reddit Google Bookmarks Newsvine Technorati Furl AIM Slashdot Yahoo






Your Recent History Page 1 of 2








NYSE


NVO

Novo Nordi..

Quote



Chart



Level 2



News



Trades



News



Financials





NASDAQ


AAL

American A..

Quote



Chart



Level 2



News



Trades



News



Financials





NASDAQ


MSFT

Microsoft

Quote



Chart



Level 2



News



Trades



News



Financials





NASDAQ


MNKD

Mannkind C..

Quote



Chart



Level 2



News



Trades



News



Financials





NYSE


PANW

Palo Alto ..

Quote



Chart



Level 2



News



Trades



News



Financials








AMEX


TNA

Direxion S..

Quote



Chart



Level 2



News



Trades



News



Financials





NASDAQ


ZYNE

ZYNERBA PH..

Quote



Chart



Level 2



News



Trades



News



Financials





NASDAQ


NTEC

Intec Phar..

Quote



Chart



Level 2



News



Trades



News



Financials





NASDAQ


GBT

GLOBAL BLO..

Quote



Chart



Level 2



News



Trades



News



Financials





NASDAQ


BNTC

Benitec Bi..

Quote



Chart



Level 2



News



Trades



News



Financials





NASDAQ


AIMT

AIMMUNE TH..

Quote



Chart



Level 2



News



Trades



News



Financials











LSE quotes are live.
All other quotes are delayed by at least 15 minutes unless otherwise stated.










© 2015 InvestorsHub.Com, Inc.

About Investor Relations (OTC:IHUBY)
About Us
Terms of Service
Privacy Policy
Advertise With Us
Investor Relations
Data Accreditations
Disclaimer

Help FAQ
Site Map
Handbook
Q&A Forum
Contact Us
Tutorials

Educational Educational Channel
Stock Market 101
Educational Videos
Investor Help Forum

More iHub on Facebook
iHub on Twitter
iHub iPhone/iPad App
iHub Android App
iHub BlackBerry App
StockWiki
Auditorium
iHub NewsWire
















Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist